At Huiyu Pharmaceuticals, our mission in the Biopharmaceuticals field is to revolutionize healthcare and positively impact the lives of billions worldwide. We recognize the substantial unmet needs in treating chronic diseases, which are frequently degenerative, debilitating, and life-threatening. In last decades, Biopharmaceuticals has been demonstrated to be more efficient to those diseases.  At Huiyu, we are developing next-generation of biologics drugs not only for cancer patients but also for chronic diseases.

Our Biopharmaceuticals division is at the forefront of advancing key therapeutic areas, including oncology, metabolism, immunology, and vaccines & immune therapies. Our R&D division integrates our R&D and Business Units, aligning them in a unified approach to deliver life-changing medicines for individuals living with common chronic diseases.

We are committed to achieving our goal of transforming healthcare. This ambition will be realized through the dedication of our talented teams and partners, who bring together scientific, medical, and commercial innovations.

The layout of innovative drug pipelines for biologics is close to the forefront of biotechnology today, including monoclonal antibodies, multi-specific antibodies, ADCs, etc.

Antibody-Drug Conjugate (ADC) development represents one of the most promising areas of innovation in cancer therapy, offering the potential to deliver highly potent cytotoxic agents directly to tumor cells while minimizing systemic toxicity. ADCs are formed by an antibody against a specific tumor-associated antigen (TAA), a cytotoxic payload, and a chemical linker that connects the TAA and the payload. Through comprehensive mining and in-depth analysis of large-scale multi-omics data generated from tumors and cancer cells, Huiyu scientists have discovered and validated novel TAAs. Combined with Huiyu's in-house developed next-generation linker payload technologies, we have developed the first-in-class ADC candidate molecules, which has demonstrated encouraging anti-tumor activity in various preclinical tumor models and good safety profiles in rodent and non-human primate toxicology studies.

Today's ADC development focuses on a small number of tumor-associated antigens (TAA) as the ADC targets. In recognizing highly heterogeneous nature of human cancers and acquired resistance inevitably evolved in response to therapies, Huiyu has strategized its ADC development by focusing on discovering and validating novel TAAs to meet unmet clinical needs. Huiyu scientists develop and apply advanced bioinformatics algorithms to integrate and mine large-scale public and private multi-omics databases to discover and validate novel TAAs.  Through Huiyu's cutting-edge antibody discovery and engineering engines, we have discovered high affinity, cancer cell-specific and efficiently internalizable mono- or multi-specific antibodies or antibody fragments suitable for the ADC development.

Equally important is the development of a library of versatile linker payloads to treat various cancer types in different therapeutic scenarios. Huiyu has developed anti-cancer drugs more than a decade. By leveraging our rich knowledge and experience accumulated in medicinal chemistry, we have developed our next generation ADC linker payload technologies. Our payload library consists of different classes of payloads, being highly drugable and versatile with a range of potency, and possessing bystander effect against heterogeneous cancer cells. The linker in an ADC is not merely a connector between the antibody and the payload but plays a critical role in the stability, selectivity, and release of the cytotoxic drug. Our propriatory linker is stable in the bloodstream to prevent premature release of the payload and yet cleavable to ensure effective payload release via defined mechanism upon reaching inside the cancer cells. Our linker is hydrophilic and supports a range of the payloads with different level of hydrophobicity at selected Drug-to-Antibody Ratio (DAR). Thus, Huiyu's linker payload technology provides an excellent opportunity of fine tuning pharmacokinetics of the ADC candidate to maximize anti-cancer efficacy while minimizing toxicity.

Our first-in-class ADC candidates derived from our novel TAA and linker payload technology have been extensively tested in various preclinical tumor models. The encouraging anti-tumor activity has demonstrated that our ADC molecule can effectively target and kill cancer cells across a range of tumor types. This broad activity is promising for the potential treatment of diverse cancer indications. Furthermore, the good safety profile observed in rodent and non-human primates toxicology studies is an essential milestone in ADC development. It provides preliminary evidence that the therapeutic window of our ADC is favorable, a critical factor in the transition from preclinical studies to human clinical trials.

As ADCs continue to evolve, the challenges of optimizing the antibody, linker, and payload components remain central to enhancing the efficacy and safety of these therapies. Our work in developing a novel ADC molecule with a proprietary linker payload technology addresses these challenges head-on and contributes to the growing body of knowledge in this exciting field of anti-tumor drug research and development.